CO MYCOPHENOLATE TABLET

Country: Kanada

Lingwa: Ingliż

Sors: Health Canada

Ingredjent attiv:

MYCOPHENOLATE MOFETIL

Disponibbli minn:

COBALT PHARMACEUTICALS COMPANY

Kodiċi ATC:

L04AA06

INN (Isem Internazzjonali):

MYCOPHENOLIC ACID

Dożaġġ:

500MG

Għamla farmaċewtika:

TABLET

Kompożizzjoni:

MYCOPHENOLATE MOFETIL 500MG

Rotta amministrattiva:

ORAL

Unitajiet fil-pakkett:

50/100

Tip ta 'preskrizzjoni:

Prescription

Żona terapewtika:

IMMUNOSUPPRESSIVE AGENTS

Sommarju tal-prodott:

Active ingredient group (AIG) number: 0128158002; AHFS:

L-istatus ta 'awtorizzazzjoni:

CANCELLED POST MARKET

Data ta 'l-awtorizzazzjoni:

2018-05-07

Karatteristiċi tal-prodott

_ _
_ _
_Page 1 of 55_
PRODUCT MONOGRAPH
PR
_CO_ MYCOPHENOLATE
Mycophenolate Mofetil Tablets USP
500 mg
Immunosuppressive Agent
Cobalt Pharmaceuticals Company
6500 Kitimat Road
Mississauga, Ontario
L5N 2B8
SUBMISSION CONTROL NO: 168316
Date of Revision:
October 16, 2013
_ _
_ _
_Page 2 of 55_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................ 3
SUMMARY PRODUCT INFORMATION
.......................................................................
3
INDICATIONS AND CLINICAL USE
.............................................................................
3
WARNINGS AND PRECAUTIONS
.................................................................................
4
ADVERSE REACTIONS
...................................................................................................
7
DRUG INTERACTIONS
.................................................................................................
15
DOSAGE AND ADMINISTRATION
.............................................................................
18
OVERDOSAGE
...............................................................................................................
20
ACTION AND CLINICAL PHARMACOLOGY
........................................................... 20
STORAGE AND STABILITY
.........................................................................................
27
SPECIAL HANDLING INSTRUCTIONS
......................................................................
27
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................ 27
PART II: SCIENTIFIC INFORMATION
..............................................................................
28
PHARMACEUTICAL INFORMATION
.........................................................................
28
CLINICAL TRIALS
.........................................................................................................
29
DETAILED PHARMACOLOGY
.............................................................................